44c 425 PCT/SE97/01098

5640

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

08/945425

Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) *Sökande* / *Applicant (s)* — *Astra AB, Södertälje SE*

(21) *Patentansökningsnummer* / *Patent application number* — *9602442-7*

(86) *Ingivningsdatum* / *Date of filing* — *1996-06-20*

Stockholm, 1997-07-31

För Patent- och registreringsverket
For the Patent- and Registration Office

Hans Järvman

Avgift
Fee

PATENT- OCH REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S 102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

ADMINISTRATION OF PHARMACEUTICALS

Field of the invention

The present invention is related to a new administration regimen of proton pump inhibitors, i.e. H^+, K^+-ATPase inhibitors. The new administration regimen gives an extended plasma concentration profile of the pharmaceutical substance, i.e. the proton pump inhibitors, thereby giving an improved inhibition of gastric acid secretion and an improved therapeutic effect. More specifically, the invention refers to the use of pharmaceutical preparations with an extended release in the treatment of gastric acid-related diseases. The pharmaceutical preparations are preferably enteric coating layered preparations and especially in the form of a tableted multiple unit dosage form with an extended release of the acid labile H^+, K^+-ATPase inhibitor. Furthermore, the present invention refers to the manufacture of such preparations.

Background of the invention

Acid labile H^+, K^+-ATPase inhibitors also named as gastric proton pump inhibitors are for instance compounds known under the generic names omeprazole, lansoprazole, pantoprazole, pariprazole and leminoprazole. Some of these compounds are for instance disclosed in EP-A1-0005129, EP-A1-174726, EP-A1-166287 and GB 2163747.

(C07D 401/12 A61K 31/44) (C07D 401/12 A61K 31/44)

These pharmaceutical substances are useful for inhibiting gastric acid secretion in mammals and man by controlling gastric acid secretion at the final step of the acid secretory pathway and thus reduce basal and stimulated gastric acid irrespective of stimulus. In a more general sense, they may be used for prevention and treatment of gastric-acid related diseases in mammals and man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer, duodenal ulcer and Zollinger-Ellison syndrom. Furthermore, they may be used for treatment f other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in

patients n NSAID therapy, in patients with Non Ulcer Dyspepsia, and in patients with symptomatic gastro-esophageal reflux disease. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre-and postoperatively to prevent acid aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the treatment of psoriasis as well as in the treatment of *Helicobacter* infections and diseases related to these.

Therapeutic control of gastric acid secretion is fundamental in all theses diseases, but the degree and duration of acid inhibition required for optimal clinical effect is not fully understood.

The duration of acid inhibition of one proton pump inhibitor such as for instance omeprazole is 3 - 4 days despite a plasma half-life of only 0.5 - 1 hour (Lind et al, Gut 1983;24:270-276)). This lack of temporal relationship between plasma concentration of omeprazole and the degree of acid inhibition is due to the long-lasting binding of the active inhibitor to the gastric pump.

Proton pump inhibitors, such as the above discussed omeprazole, are generally administered as a single daily dose of 20 mg or 40 mg, depending on the gastrointestinal disorder as well as the severity of the disease. In the treatment of Zollinger-Ellison syndrom higher dosages of 60 - 120 mg/daily and as much as 360 mg/daily have been used. Generally, the proton pump inhibitor is adminstered to the patient during 2 - 4 weeks, in some cases up to 8 weeks. Omeprazole has also been used as maintainace therapy for peptic ulcer disease and reflux esophagitis during many years.

Despite this long duration of acid inhibition once daily dosing results in not more than 70-80 % inhibition of maximal acid output prior to next dose. Results from *Helicobacter pylori* eradication studies have shown an improved efficacy with twice daily dosing in combination with antimicrobials and treatment of severe GERD is also improved by divided doses as compared to single dose increments. These improved clinical effects are due to longer periods f high acid inhibition.

Although action of proton pump inhibitors is c valent, efficacy depends on active pumps and there are two pools of pumps, active and inactive. Only active pumps are covalently inhibited. The inactive pumps are recruited throughout the day therefore effectiveness of acid inhibition improves for 72 hours on once a day treatment, steady state being achieved as a balance between inhibition of active pumps and de novo biosynthesis or reversal of inhibition.

Extended release formulations to give plasma levels extending from 6-12 hours (by any of several means) will result in a larger fraction of the pumps being inhibited and should result in more effective inhibition of acid secretion resulting in improved efficacy in GERD, more rapid healing of gastric ulcer and improved eradication of *H. Pylori*.

Summary of the invention

On a once a day administration regimen the maximal effect of omeprazole is about 75 to 80 %, 24 hours after dose (Lind et al 1986, Scand J Gastroenterol (Suppl 118): 137 - 8 and Lind et al 1988, Scand J Gastroenterol 23: 1259 - 66), i.e. about 20 to 25 % of the maximal gastric acid secretory capacity is present 24 hours after the dose. Even if an increased dose quantity of the proton pump inhibitor has been used (See Lind et al) the maximal gastric acid inhibition is limited to about 80 %.

The known dose dependency of gastric acid inhibition has hithereto resulted in a recommendation to initially increase the dose of the proton pump inhibitor, if a low response on the therapy or lack of response is received.

It has now been proposed according to the present invention to extend the plasma concentration profile of proton pump inhibitors and thereby improving their therapeutic effect. According to one aspect of the invention, the extended plasma profile is provided by two or more consecutive administrations of a unit dose of a proton pump inhibitor with 0.5-4 hours interval. According to another aspect of the invention, the extended plasma profile

of the proton pump inhibitor is provided by a dosage form giving an extended release of the compound, such a controlled release preparation/composition of the proton pump inhibitor will maintain once daily dosing.

Detailed description of the invention

Acid secretion by the gastric mucosa is a property of the parietal cell. Whereas the functional regulation of this cell is a complicated process involving several different cell types with different receptors, acid transport per se is the property of a single P-type ATPase, the gastric H^+, K^+-ATPase. Therefore, effective therapeutic control of acid secretion involves either receptor blockade or gastric H^+K^+-ATPase inhibition. This invention relates to the proton pump inhibitors and their reaction with the gastric acid pump. The half-life in plasma of the proton pump inhibitors is rather short. The administered proton pump inhibitor reacts with the number of active gastric acid pumps available for inhibition during that time. Un-inhibited pumps will be available during the time and pumps will recover following biosynthesis and reversal of inhibition. Therefore, by a repeated regimen or a dosage form with an extended plasma profile recovered pumps as well as un-inhibited pumps not previously available will react with the newly administered dose of pharmaceutical substance or the continuously released substance.

By administration of a pharmaceutical dosage form with an extended release, the plasma concentration of the pharmaceutical substance can be kept on a high level during an extended time. As a result the number of pumps inhibited by the proton pump inhibitor will increase and a more efficient therapeutic control of acid secretion will be obtained.

Compounds of interest for the novel administration with a repeated dosing regimen as well as for the extended release preparations/compositions giving an extended plasma profile according to the present invention are compounds of the general formula I



I

wherein

Het_1 is



or



Het_2 is



or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R_6-R_9 optionally may be exchanged for a nitrogen atom without any substituents;

R_1, R_2 and R_3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R_4 and R_5 are the same or different and selected from hydrogen, alkyl and aralkyl;

R_6' is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R_6-R_9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R_6-R_9 form ring structures which may be further substituted;

R_{10} is hydrogen or forms an alkylene chain together with R_3 and

R_{11} and R_{12} are the same or different and selected from hydrogen, halogen or alkyl.

Examples of specifically interesting compounds according to formula I are



(Ia)



















The compound used in the administration regimen as well as in the extended release preparations according to the present invention may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg^{2+}, Ca^{2+}, Na^{+} or K^{+} salts, preferably the Mg^{2+} salts. The compounds may also be used in the form of one of its single enantiomers or an alkaline salt of the single enantiomer.

These compounds are susceptible to degradation/transformation in acidic and neutral media. Generally, the degradation is catalyzed by acidic reacting compounds and the active compounds are stabilized with alkaline reacting compounds. Thus, the substances being acid labile proton pump inhibitors are best protected from contact with acidic gastric juice by an enteric coating. There are different enteric coating layered preparations comprising omeprazole as well as other proton pump inhibitors described in the prior art, see for instance US-A 4,853,230. An enteric coated tablet of omeprazole magnesium salt is described in WO 95/ 01783. A tableted muliple unit dosage form of omeprazole is described in WO 96/ 01623. Pharmaceutical preparations manufactored according to known principles as described in the specifications US-A 4,853,230, WO 95/ 01783 and WO 96/ 01623, hereby incorporated in whole by references, may be used for administration with an increased dosing frequency according to the present invention.

An unit dosage of the proton pump inhibitor, for instance 1 - 500 mg is administered at least twice a day. The unit dosage may be given with a dosing frequency of about 0.5 - 4 hours, preferably two doses are given during a time period of 2 to 3 hours. Suitable doses comprise for instance 5, 10, 15, 20, 30 and 40 mg of the pharmaceutical substance.

Alternatively, an oral pharmaceutical formulation with extended release of the pharmaceutical substance during 2 - 12 hours, preferably 4 - 8 hours may be administered. Such an extended release preparation may comprise up to 500 mg of the substance, preferably the doses comprise about 1 - 500 mg of the substance, and more preferably 10 - 80 mg.

Different techniques for manufactoring various controlled release preparations are for example described in Aulton M.E. (Churchill Livingstone Ed.), Pharmaceutics: The science of dosage form design (1988), p. 316-321.

The invention is described more in detail by the following examples.

Examples

Two doses of omeprazole was given to healthy subjects, 10 - 20 mg omeprazole in the morning and 10 - 20 mg omeprazole 3 hours later during 5 days. Basal acid output and pentagastrin stimulated maximal output were measured. The result was compared to an once a day regimen of 20 - 40 mg omeprazole.

Claims

1. An administration regimen giving an extended plasma profile of a pharmaceutical substance characterized in that the substance is a H^+, K^+-ATPase inhibitor, and that the extended plasma profile is received by two or more consecutive administrations of a unit dose of the H^+, K^+ - ATPase inhibitor with 0.5 - 4 hours interval.

2. An administration regimen according to claim 1 characterized in that the H^+, K^+-ATPase inhibitor is a compound with the formula I



I

wherein

Het_1 is



or



Het_2 is



or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R_6-R_9 optionally may be exchanged for a nitrogen atom without any substituents;

R_1, R_2 and R_3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R_4 and R_5 are the same or different and selected from hydrogen, alkyl and aralkyl;

R_6' is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R_6-R_9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R_6-R_9 form ring structures which may be further substituted;

R_{10} is hydrogen or forms an alkylene chain together with R_3 and

R_{11} and R_{12} are the same or different and selected from hydrogen, halogen or alkyl.

3. An oral pharmaceutical composition giving an extended plasma profile of a pharmaceutical substance characterized in that the active substance is a H^+, K^+-ATPase inhibitor.

4. An oral pharmaceutical composition according to claim 3 characterized in that the extended plasma profile is received during 2 - 12 hours.

5. An oral pharmaceutical composition according to claim 3 characterized in that the H^+, K^+-ATPase inhibitor is a compound with the formula I



I

wherein

Het_1 is



or



Het_2 is



or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R_6-R_9 optionally may be exchanged for a nitrogen atom without any substituents;

R_1, R_2 and R_3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R_4 and R_5 are the same or different and selected from hydrogen, alkyl and aralkyl;

R_6' is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R_6-R_9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R_6-R_9 form ring structures which may be further substituted;

R_{10} is hydrogen or forms an alkylene chain together with R_3 and

R_{11} and R_{12} are the same or different and selected from hydrogen, halogen or alkyl.

6. Use of an oral pharmaceutical composition as claimed in claim 3 in the manufacture of a medicament with improved inhibition f gastric acid secretion.

7. Use of an oral pharmaceutical c mposition as claimed in claim 3 in the manufacture of a medicament with improved therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion.

8. Use of H^+, K^+ - ATPase inhibitor with the formula I defined in claim 5, for the preparation of a pharmaceutical composition with extended release.

9. A method for improving inhibition of gastric acid secretion with comprises administering to a patient in need thereof, an oral pharmaceutical composition as claimed in claim 3.

10. A method for improving the therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a patient in need thereof, an oral pharmaceutical composition as claimed in claim 3.

11. A method for receiving an extended plasma profile of a H^+, K^+ - ATPase inhibitor by administering to a patient in need thereof a pharmaceutical preparation with extended release of said H^+, K^+ - ATPase inhibitor.

Abstract

A new adminstration regimen giving an extended plasma concentration profile of a H^+, K^+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administraticns of a unit dose of a H^+, K^+ - ATPase with 0.5 - 4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.